Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Alejandro Miguel Martin Dunn

Glay Chinea Santiago

Alexis Musacchio Lasa

Osmany Guirola Cruz

Vivian Huerta Galindo

Noralvis Fleitas Salazar

Patricia Gabriela Toledo Mayora

Osvaldo Reyes Acosta

Hilda Elisa Garay Perez

Hilda Elisa Garay Pérez

Maria De Jesus Leal Angulo

Anabel Alvarez Acosta

Ania Cabrales Rico

Mónica Sarría Núñez

Consuelo Nazabal Galvez

Diogenes Quintana Vazquez

Gabriel Ramon Padron Palomares

Vladimir Armando Besada Perez

Monica Sarria Nunez

Aniel Sanchez Puente

Recardo De La Caridid Siva Rodriquez

Carmen Elena Gomez Rodriquez

Olvaldo Reyes Acosta

Luis Emilio Carpio Munoz

Anìa Cabrales Rico

Enrique Gerardo Guillen Nieto

Carlos Antonio Durate Cano

Luis Javier Gonzalez Lopez

Alexis Yero Diaz

Gabriel Jesus Marquez Perera

Karen Alvarez Perez

Rocio Garateix Suarez

Dianne Pupo Gomez

Sonia Gonzalez Blanco

The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.

Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family

The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.

Method to block the infection by flaviviruses, molecules and uses

The present invention related to biotechnology and genetic engineering, particularly the expression of proteins of viral origin in microorganisms through their fusion by applying recombinant DNA technology to bacterial peptides. The present invention provides an effcient process for the expression inof heterlogous proteins as fusion peptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations. What is essentially used is a stabilizing sequence derived from the first 47 amino acids of the antigen P64k ofB:4:P1.15. In particular, use is made of a recombinant plasmid containing said sequence, under the control of the tryptophane promoter ofand of the terminator of the transcription of the phage T4, including restrictions sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest.

Monoclonal antibody to the stabilizer peptide of the P64K antigen of Neisseria meningitidis

Growing community of inventors

Ciudad de la Habana, Cuba

Alejandro Miguel Martin Dunn